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Abstract 
The tumor suppressor phosphatase and tensin homolog deleted on chromosome 10 (PTEN) is 
a negative regulator of the phosphatidylinositol 3-kinase (PI3K)/Akt signaling pathway. Akt 
activation exerts a strong anti-apoptotic effect and inhibits key pro-apoptotic proteins. We 
investigated the effect of caffeine in the prevention of tumor cell proliferation and induction 
of cell death. We found that caffeine induced increased intracellular cAMP levels, PTEN 
activation, and Akt inactivation, which together prevented proliferation of human 
osteosarcoma cells (MG63) and fibrosarcoma cells (HT1080). PTEN-knockdown by siRNA 
reduced the effects of caffeine on Akt inactivation in osteosarcoma cells. These results 
indicate that the tumor suppressor PTEN signaling pathway contributes to the 
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growth-inhibitory effect of caffeine on sarcoma cells. Our data suggests that caffeine and 
other drugs that act on this pathway could have promising therapeutic effects in the treatment 
of sarcoma patients. 
 
Introduction 
Caffeine, a methylxanthine derivative, increases cAMP by inhibiting phosphodiesterase 
(PDE) activity, and is well-known to have diuretic and central-nervous system stimulatory 
effects. On the other hand, caffeine is an inhibitor of ataxia telangiectasia mutated (ATM) and 
ATM-Rad3-related (ATR) kinases, which are master regulators of DNA damage-induced cell 
cycle checkpoints (1,2). Therefore, caffeine has both anti-cancer or anti-carcinogenic effects 
and the ability to enhance the cytocidal activity of anticancer drugs by inhibiting DNA repair 
pathways (3-5). Based on these studies, we developed caffeine-assisted chemotherapy for 
bone and soft tissue sarcoma. While the five-year survival rates of patients with 
osteosarcomas are still only 60-70% (6-8), we previously reported that caffeine-assisted 
chemotherapy induced a complete response in more than 80% of patients with osteosarcoma 
(9), and an enhancement of the five-year survival rate to approximately 90% (10). These 
results indicate that caffeine is a beneficial agent for the treatment of malignant bone and soft 
tissue tumors such as osteosarcoma (11-14), but the molecular mechanism of caffeine in these 
diseases has not yet been fully elucidated.  
The tumor suppressor gene PTEN (phosphatase and tensin homolog deleted in 
chromosome 10, 10q23.3) protein has been identified as a tumor suppressor in cancers of the 
prostate, breast, and endometrium (15-17). PTEN is a pivotal protein that regulates the 
balance between cell growth and death. PTEN and Phosphoinositide 3-kinase (PI3K) have 
3 
 
opposing effects on Akt regulation (18, 19). Akt in turn inhibits several downstream targets 
including the apoptosis-inducing protein BAD (20), p27 (21), and cyclin-dependent kinase 
(22), resulting in cell growth and survival. 
We speculated that PTEN may be involved in the molecular mechanisms that are 
responsible for caffeine’s antitumor effects. In this study, we found that caffeine activated 
PTEN by elevating intracellular cAMP levels, resulting in inhibition of Akt activity and 
induction of apoptosis. 
 
Materials and Methods 
Reagents and antibodies 
RPMI-1640 medium with L-glutamine, phenol red, caffeine, and the PDE inhibitor, 
isobutylmethylxanthine (IBMX), were from Wako Pure Chemical Industries, Ltd. (Osaka, 
Japan); fetal bovine serum (FBS) was from Sigma (St. Louis, MO, USA); and penicillin and 
streptomycin were from Gibco-Invitrogen (Carlsbad, CA, USA). Cisplatin was from Nippon 
Kayaku (Tokyo, Japan). The adenylate cyclase stimulator, forskolin, and vasodilator 
stimulated phosphoprotein (VASP) were obtained from Calbiochemical (La Jolla, CA). 
Antibodies with the following specificities were obtained from Cell Signaling Technology, 
Inc. (Beverly, MA): PTEN, phospho-specific PTEN (Ser380), Akt, and phospho-specific Akt 
(Ser473), β-actin, phospho-specific VASP, and cleaved caspase 3.  
Cell culture 
Human osteosarcoma cell line MG63 and human fibrosarcoma cell line HT1080 were 
obtained from the American Type Culture Collection (Rockville, MD). Both cell lines were 
maintained in RPMI 1640 supplemented with 10% fetal bovine serum, penicillin and 
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streptomycin at 37°C in 5% CO2. 
Cell proliferation assay 
Cell proliferation was analyzed with Cell Counting Kit 8 (DOJINDO, Japan). MG63 and 
HT1080 cells were seeded in 96 well plates at a density of 1 × 104 cells/well. After 24 h 
incubation, the cells were treated or not treated with 0.25-5 mM caffeine, or 1 mM IBMX, 
and/or 2 μg/ml cisplatin for 72 h. IBMX, a PDE inhibitor, was used in this assay to 
demonstrate that PDE-inhibition participates in the inhibitory effect of caffeine on cell 
proliferation. The cells were incubated with 10 μl WST-8 for 2 h. Absorbance of the colored 
formazan product produced by mitochondrial dehydrogenases in metabolically active cells 
was recorded at 450 nm as background. Cell proliferation was expressed as the percentage of 
absorbance obtained in the treated wells relative to that in the untreated control wells. The 
concentration of caffeine corresponding to 50% cell death indicates IC50. 
PTEN and Akt activity assays 
To determine the effect of caffeine on PTEN and Akt activities, we investigated the levels of 
phospho-PTEN and phospho-Akt following various stimulations. Increases in 
phospho-PTEN/phospho-Akt levels indicated PTEN-inactivation and Akt-activation. MG63 
cells were incubated in RPMI without serum for 24 h, and treated with caffeine (0, 1, 5 mM), 
IBMX (0.1, 1 mM) and/or forskolin (0.1 mM) for 30 min. Cells extracts were immunoblotted 
using anti-phospho-PTEN (Ser380), anti-PTEN, anti-phospho-Akt (Ser473), anti-Akt 
antibodies or anti-phospho-VASP. In this assay, phospho-VASP and forskolin were used to 
determine that the proliferation-inhibitory effect of caffeine depends on increases in cAMP 
levels.  
Western blot analysis 
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Western blot analyses were performed as described previously (23, 24). All antibodies were 
used at a dilution of 1:1000. 
Silencing of PTEN with small interfering RNA (siRNA). 
Single-stranded human PTEN specific sense and antisense RNA oligonucleotides and control 
scrambled oligonucleotide were synthesized by in vitro transcription using the siTrio Full Set 
(# SHF27A-1888, B-Bridge International, Inc. USA) and annealed to generate a RNA duplex. 
The MG63 cells were transfected with small interfering RNA (100 μM) using Lipofectamine 
2000 before experiments.   
Statistical analysis. 
Data are presented as means ± SEM from at least three independent experiments. Statistical 
analysis was performed by ANOVA followed by Dunnett’s test. 
 
Results 
Caffeine inhibits proliferation of MG63 cells in a dose-dependent manner. 
The proliferation of caffeine-treated MG63 osteosarcoma cells decreased in a dose-dependent 
fashion (IC50= 2.70 mM) (Figure 1A).  
Caffeine decreases the amount of phosphorylated PTEN and Akt in MG63 cells. 
Caffeine treatment of MG63 cells also decreased the levels of phospho-PTEN 
(inactivated-PTEN) and phospho-Akt (activated-Akt) in a dose-dependent manner (Figure 1B, 
C), with the phosphorylated protein levels dropping by more than 50% while the overall 
protein amount remained constant. These results suggest that caffeine induces 
concentration-dependent activation of PTEN and inactivation of Akt. 
PTEN depletion prevents caffeine-mediated Akt inhibition. 
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To obtain direct evidence that dephosphorylated PTEN is required for Akt inactivation by 
caffeine, we tested the effects of caffeine when PTEN protein was depleted by small 
interfering RNA. Akt phosphorylation was decreased by caffeine in control cells, but in 
PTEN knock-down cells caffeine-induced Akt inhibition was significantly reduced (Figure 
1D). This result confirmed that Akt inactivation by caffeine is dependent on PTEN activation.  
Caffeine and IBMX inhibit cell proliferation, phosphorylation of PTEN and Akt, and 
induce phosphorylation of VASP in MG63 cells. 
Proliferation of MG63 cells was inhibited by caffeine and the PDE inhibitor IBMX (Figure 
2A). In contrast, the level of phospho-VASP was increased by caffeine or IBMX (Figure 2B). 
VASP is a crucial factor in regulating actin dynamics, and the increased amount of 
phospho-VASP is an indication of the elevated intracellular cAMP concentrations (25). Since 
levels of phospho-PTEN and phospho-Akt were decreased by caffeine or IBMX in MG63 
cells (Figure 2C, D), the increased cAMP levels that result from PDE inhibition might lead to 
PTEN activation, Akt inactivation, and subsequently inhibition of MG63 cell proliferation. 
Forskolin supports the inhibition of Akt/PTEN phosphorylation by caffeine in MG63 
cells. 
To confirm that increased cAMP decreases the amount of phospho-PTEN and phospho-Akt, 
we tested the effects of forskolin, caffeine, and IBMX on MG63 cells. Caffeine and IBMX 
inhibit PDE, resulting in increased intracellular cAMP, while forskolin increases cAMP levels 
by stimulating adenylate cyclase. The level of phospho-VASP was slightly increased by a low 
dose of forskolin (Figure 3A), as well as low doses of caffeine or IBMX (data not shown). 
However, low doses of forskolin together with caffeine or IBMX strongly increased the 
amount of phospho-VASP, indicating that the combination of low doses of forskolin and 
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caffeine/IBMX synergistically increased intracellular cAMP (Figure 3A). These results 
suggest that forskolin leads to increased cAMP levels, which are immediately reduced 
because of the high PDE activity in MG63 cells. This possibility is supported by our results 
showing that treatment of MG63 cells with forskolin alone only slightly reduced the levels of 
phospho-Akt and phospho-PTEN (Figure 3B, C). The levels of phospho-PTEN and 
phospho-Akt were markedly decreased by combined treatment with forskolin and caffeine. 
Treatment with IBMX in combination with forskolin also significantly decreased the amounts 
of phospho-PTEN and phospho-Akt. Together, these results suggest that increased cAMP 
induces activation of PTEN and inactivation of Akt. 
Caffeine decreases the level of phosphorylated PTEN and Akt in human fibrosarcoma 
HT1080 cells. 
As with MG63 cells, the proliferation of HT1080 fibrosarcoma cells was reduced by caffeine 
in a dose-dependent manner (IC50=2.22 mM), and also by IBMX (Figure 4A). In addition, 
the level of phospho-VASP in HT1080 cells was also increased by caffeine and IBMX, and 
the amounts of phospho-PTEN and of phospho-Akt were decreased by caffeine and IBMX 
(Figure 4B). These results suggest that the caffeine-induced increase of cAMP may lead to 
PTEN activation, Akt inactivation, and inhibition of proliferation in HT1080 cells as well. 
Caffeine enhances the antitumor effect of cisplatin on MG63 cells.  
Proliferation of MG63 cells treated with 0.5 mM caffeine or 2 μg/ml cisplatin decreased by 
~20% and 40%, respectively (Figure 5A), while the proliferation of cells treated with both 
cisplatin and caffeine was markedly decreased by more than 80%. The amount of cleaved 
caspase 3, an apoptosis marker, was increased by treatment with cisplatin, and markedly 
increased by treatment with both caffeine and cisplatin (Figure 5B). In contrast levels of 
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phospho-PTEN and phospho-Akt were significantly decreased by the treatment of cells with a 
combination of caffeine and cisplatin (Figure 5B). These results indicate that caffeine 
enhances the induction of apoptosis by cisplatin, confirming that our caffeine-assisted 
chemotherapy enhanced the treatment of osteosarcoma. 
 
Discussion 
Our results provide new insight into PTEN activation in the context of caffeine assisted 
sarcoma treatments (Figure 6). Intracellular cAMP also plays an important role in 
caffeine-regulated PTEN activation. PTEN, a lipid phosphatase specific for 
phosphatidylinositol (3, 4, 5)P3 (PIP3), and PI3K have opposing effects on cellular PIP3 
levels and consequently regulate cell proliferation and survival through various signaling 
molecules, especially Akt. Dephosphorylation of PIP3 by PTEN leads to inhibition of Akt 
activity. In this study, we showed that caffeine-induced increases in intracellular cAMP 
activate PTEN, in turn inhibiting Akt (Figure 1, 4) and subsequently inducing caspase-3 
activation and apoptosis (Figure 5). 
Osteosarcoma is the most common primary malignant bone tumor in children and 
young adults. During the last few decades, the prognosis of patients with osteosarcoma has 
been remarkably improved by a combination of surgical and chemotherapeutic treatments (6). 
At our institute, caffeine-assisted multi-agent chemotherapy improved the treatment success 
of malignant bone and soft tissue tumors such as osteosarcoma (10). While conventional 
multi-agent chemotherapies yield a local tumor response of approximately 63% and a 
five-year survival of 67.5% for non-metastatic osteosarcoma (6), the response rate of 
caffeine-assisted chemotherapy was over 80%, and the five-year survival rate was 90% 
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(five-year event-free rate, 76%) for primary non-metastatic osteosarcoma (10). These results 
indicate that caffeine-assisted multi-agent chemotherapy is superior to conventional 
multi-agent chemotherapies for the treatment of osteosarcoma, but the molecular mechanism 
of caffeine in this disease has not yet been fully elucidated. 
Caffeine, a purine alkaloid, is a key component of many popular drinks, most notably 
tea and coffee, and is well known as a stimulatory agent because of its excitatory effects on 
nervous/humoral regulation. Methylxanthines, including caffeine and theophylline, increase 
cAMP by inhibiting PDE. We showed that caffeine increased phosphorylation of VASP, 
indicating elevated intracellular cAMP levels, and also increased the activity of PTEN while 
decreasing Akt activity in osteosarcoma cells, similarly to the general PDE inhibitor IBMX 
(Fig. 2). We observed that forskolin, an adenylate cyclase stimulator, reinforced the effects of 
caffeine on increasing intracellular cAMP and PTEN activity, and decreasing Akt activity in 
osteosarcoma cells (Fig. 3). These results suggested that production of cAMP by caffeine 
might regulate PTEN and Akt activity. Canetti et al. (26) reported that the exchange protein 
activated by cAMP (Epac)-1 agonist induces an increase in PTEN lipid phosphatase activity. 
Increased intracellular cAMP levels activate Epac-1, in turn causing an increase in SHP-1 
phosphatase activity that is responsible for PTEN activation. Additional experimentation will 
be needed to define the mechanism of cAMP effects on PTEN activation in greater detail. 
 Akt is activated by PIP3, which is produced by PI3K and reduced by PTEN. 
Inactivation of Akt by caffeine suggests two possibilities: activation of PTEN or inactivation 
of PI3K. Nomura et al. (27) reported that caffeine suppressed phosphorylation and activation 
of Akt without inhibiting PI3K activation, thereby supporting our conclusion that 
caffeine-induced activation of PTEN inactivates Akt. To confirm that PTEN participated in 
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the effect caused by caffeine, PTEN was depleted by siRNA. In PTEN-knockdown cells, 
caffeine-mediated inactivation of Akt was markedly weakened (Fig. 1-D). This result 
supports an important role for PTEN in caffeine-induced antitumor effects. 
 Caffeine has also been shown to sensitize tumor cells to ionizing radiation and other 
genotoxic agents (28, 29). Caffeine inhibits ATM and ATR, proximal components of induced 
DNA damage, and cell cycle checkpoint pathways. ATM and ATR inhibit the passage of 
DNA-damaged cells from G2 to M phase, causing increased genomic instability. These 
results are supported by the findings that caffeine increases radiosensitivity, UVB-induced 
skin carcinogenesis, and sensitivity to chemotherapeutic agents. Moreover, some reports 
indicate that caffeine independently induces cellular apoptosis (29-31). Consistent with 
previous studies, the present study showed that caffeine induces apoptosis in osteosarcoma 
and fibrosarcoma cells (Fig. 1 and 4). Although caffeine is known to affect p53, Bax, Akt, and 
other apoptosis-related proteins (3), there have been no reports about caffeine’s effect on the 
tumor suppressor protein, PTEN. In this study, we showed that PTEN is involved in 
caffeine-induced antitumor effects. 
Work by He et al. (3) indicated that low concentrations of caffeine induced 
p53-dependent apoptosis via the Bax and caspase 3 pathways but this response was not 
induced in p53-/- cells. PTEN is believed to control p53 protein stability, both in a 
phosphatase-dependent and phosphatase-independent manner through interactions with p53 
(32, 33). Furthermore, PTEN-p53 interactions have been demonstrated to enhance p53 DNA 
binding to endogenous p21 promoters (32, 33). Taken together, these results suggest the 
possibility that caffeine stabilizes and activates p53 through the activation of PTEN. 
Our results demonstrated that caffeine enhances the apoptosis-inducing cytotoxicity 
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of cisplatin (Figure 6). Cisplatin increased the level of cleaved caspase 3, and this response 
was enhanced by caffeine. Thus, this mechanism likely explains the caffeine-assisted 
chemotherapeutic outcome in patients at our institutes.  
In summary, our data provide novel insights into the mechanism by which caffeine 
induces apoptosis in osteosarcoma and fibrosarcoma cells. We demonstrate for the first time 
that caffeine activates PTEN, which antagonizes the stimulatory effects of PI3K in 
osteosarcoma cells and fibrosarcoma cells. This limits PI3K signaling, resulting in a 
suppression of downstream activation pathways such as Akt which are critical for 
anti-apoptotic functions. Our data demonstrate that these effects on PTEN are mediated by 
cAMP. These findings provide fundamental new insights into the regulation of 
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Figure 1. Caffeine inhibits proliferation and decreases the level of PTEN and Akt 
phosphorylation in MG63 cells. MG63 cells were cultured in 100 μl 5% FBS/RPMI in 
96-well plates (1 × 103/well). After 24 h, cells were exposed to 0-5 mM caffeine for 72 h. 
Results were determined with the cell proliferation assay. Data were calculated as a 
percentage of untreated controls. Caffeine decreased proliferation of MG63 cells in a 
dose-dependent manner (A). **p<0.01.  MG63 cells were cultured in 2 ml 5% FBS/RPMI 
(1 × 105/35 mm dish). After 24 h incubation, the cells were treated with 1 mM, or 5 mM 
caffeine for 30 min. Cells were disrupted with lysis buffer and expression of phospho-PTEN, 
total-PTEN, phospho-Akt, and total-Akt was measured by Western blotting. Caffeine 
decreased phosphorylated PTEN (B) and decreased phosphorylated Akt (C) in a 
dose-dependent manner. These results suggest that caffeine inhibits cell proliferation and 
increases PTEN activation and Akt inactivation.  
PTEN+ and PTEN-knockdown (generated with siRNA) MG63 cells (1 × 105) were 
suspended in 0.5% FBS/RPMI for 24 h and then treated with 5 mM caffeine for 30 min. Cells 
were disrupted with lysis buffer and levels of phospho-Akt, total-Akt, and total-PTEN were 
measured by Western blotting. The level of phospho-Akt was decreased by caffeine in the 
control cells, but the decrease was reduced in PTEN knockdown cells (D). Thus, PTEN 
participates in caffeine-mediated Akt inactivation. Data are expressed as a mean ± SEM of 
independent three experiments. *P<0.05, **P<0.01 vs untreated controls. 
Figure 2. Caffeine and IBMX phosphorylate VASP and decrease MG63 cell proliferation. As 
in Figure 1A, MG63 cells were treated with 0.25-5 mM caffeine, or 1 mM IBMX for 72 h. 
Then, cell proliferation was analyzed with the cell proliferation assay. Caffeine and IBMX 
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decreased proliferation of MG63 cells (A). MG63 cells were incubated in RPMI without 
serum for 24 h, and the cells were treated with 5 mM caffeine, or 1 mM IBMX for 30 min. 
Cellular extracts were immunoblotted using anti-phospho-VASP, anti-β-actin, 
anti-phospho-PTEN, anti-PTEN, anti-phospho-Akt, and anti-Akt antibodies. As in Figure 1B 
and C, caffeine and IBMX increased the phosphorylation of VASP (B) and reduced 
phosphorylation of PTEN and Akt (C, D). Therefore, caffeine and IBMX increase the level of 
cAMP, resulting in PTEN activation and Akt inactivation. Data are expressed as a mean ± 
SEM of independent three experiments. *p<0.05, **p<0.01 vs untreated controls.  
Figure 3. Forskolin enhances PTEN activation and Akt inactivation by caffeine and IBMX in 
MG63 cells. MG63 cells were cultured in 2 ml 5% FBS/RPMI (1 × 105/35 mm dish). After 24 
h incubation, the cells were treated with a low dose of forskolin (0.1 mM) alone, or combined 
with a low dose of caffeine (0.5 mM) and/or IBMX (0.1 mM) for 30 min. The expression of 
phospho-VASP, phospho-PTEN, and phospho-Akt was measured by Western blotting. Data 
are expressed as a mean ± SEM of independent three experiments. **P<0.01 vs untreated 
controls. Levels of phospho-VASP were slightly increased by forskolin, and markedly 
increased by combining with caffeine or IBMX (A). The Levels of phospho-PTEN and 
phospho-Akt were markedly decreased by combining forskolin with caffeine or IBMX (B, C). 
Thus, cAMP participates in caffeine-mediated PTEN activation and Akt inactivation. 
Figure 4. Caffeine reduces growth and decreases phosphorylation of PTEN and Akt in 
HT1080 cells. As in Figure 1, caffeine reduced growth of HT1080 cells in a dose-dependent 
manner (A) and reduced phosphorylation of PTEN and phosphorylation of Akt, and increased 
phosphorylation of VASP (B) in HT1080 cells. **p<0.01. Thus, caffeine reduces proliferation 
via PTEN activation and Akt inactivation in both osteosarcoma cells and other sarcoma cells.  
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Figure 5. Caffeine enhances growth inhibition and pro-apoptotic pathway activation in MG63 
cells exposed to cisplatin. As in Figure 1, MG63 cells were cultured in 96 well plates (1 × 
103/well) and treated with or without 2 μg/ml cisplatin, followed by incubation with a low 
dose of caffeine (0.5 mM; similar to the concentration in human treatments) for 72 h. Then, 
cell proliferation was determined by cell proliferation assay (A). Cells treated with 0.5 mM 
caffeine, or 2 μg/ml cisplatin had decreased amount of proliferation, which markedly 
decreased upon treatment of cells with both cisplatin and caffeine. Next, 1 × 105 MG63 cells 
were cultured in 35 mm dishes (1 × 105/dish) for 24 h and then exposed to either 0.5 mM 
caffeine, or 2 μg/ml cisplatin, or both. The level of phospho-PTEN, phospho-Akt, cleaved 
caspase 3, and β-actin was determined by Western blot analysis (B). Cisplatin decreased the 
level of p-Akt and p-PTEN, and increased the level of cleaved caspase 3. Caffeine enhanced 
cisplatin-induced apoptosis. Thus, caffeine enhances the cytotoxicity of anticancer agents. 
**p<0.01. 
Figure 6. Schematic diagram showing how caffeine induces apoptosis in osteosarcoma cells.  
Akt promotes cell proliferation and survival by inactivating apoptosis-inducing molecules. 
Akt activation is counter balanced by PTEN activity, which provides a negative regulation of 
PI3K signaling and reduces the level of PIP3 available for Akt recruitment. Our data indicate 
that caffeine activates PTEN through the elevation of intracellular cAMP, resulting in 
inhibition of Akt. 
PDE: phosphodiesterase; AC: adenylate cyclase; PKA: protein kinase A; VASP: vasodilator 
stimulated phosphoprotein; Epac-1: exchange protein activated by cAMP-1; SHP-1: 
SH2-containing phosphatase 1; PIP2: phosphatidylinositol 3,4-bisphosphate; PIP3: 
phosphatidylinositol 3,4,5-trisphosphate; PI3K: phosphoinositide 3 kinase  
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